(RTTNews) - Acurx Pharmaceuticals, Inc. (ACXP) Monday announced that its lead antibiotic candidate, ibezapolstat, is advancing to international Phase 3 clinical trials for treating C. difficile ...

Factors linked to C difficile infection in patients with IBD include IBD activity prior to infection, shorter disease duration, previous use of corticosteroids, and prior hospitalisation.

C diff brings on diarrhea and colitis, an inflammation of the colon, and is responsible for nearly 500,000 infections annually in the United States. The stubborn superbug known as C diff ...